Trials / Completed
CompletedNCT02207725
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
A Phase 3 Randomized, Double-Blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Apixaban Anticoagulation With Intravenously Administered Andexanet Alfa
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Portola Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Andexanet | |
| OTHER | Placebo |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-04-01
- Completion
- 2015-09-01
- First posted
- 2014-08-04
- Last updated
- 2023-08-08
- Results posted
- 2018-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02207725. Inclusion in this directory is not an endorsement.